1,2,4-Triazine-3,5(2H,4H)-dione,2-b-D-ribofuranosyl- cas no:54-25-1
Synonyms: as-Triazine-3,5(2H,4H)-dione,2-b-D-ribofuranosyl- (6CI,7CI,8CI);2-b-D-Ribofuranosyl-as-triazine-3,5(2H,4H)-dione;6-Azauracil 1-riboside; 6-Azauracil riboside; 6-Azauracil-b-D-riboside; 6-Azauridine;6-Azur; 6-Azuridine; AzUR; Azauridine; NSC 32074; Rib-Azauracil; Ribo-azuracil;Riboazauracil; ribo-Azauracil
Name1,2,4-Triazine-3,5(2H,4H)-dione,2-b-D-ribofuranosyl-
CAS54-25-1
Synonymsas-Triazine-3,5(2H,4H)-dione,2-b-D-ribofuranosyl- (6CI,7CI,8CI);2-b-D-Ribofuranosyl-as-triazine-3,5(2H,4H)-dione;6-Azauracil 1-riboside; 6-Azauracil riboside; 6-Azauracil-b-D-riboside; 6-Azauridine;6-Azur; 6-Azuridine; AzUR; Azauridine; NSC 32074; Rib-Azauracil; Ribo-azuracil;Riboazauracil; ribo-Azauracil
EINECS(EC#)200-199-6
Molecular FormulaC8H11 N3 O6
Molecular Weight245.22
refractive index1.795
storage temp2-8°C
Hazard Xn: Harmful;
Risk R20/21/22
Safety
Moderately toxic by intraperitoneal route. Human teratogenic effects by intravenous route: unspecified developmental abnormalities or effects on the embryo or fetus. An experimental teratogen. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx. Used as an antineoplastic agent.
Hazard Codes: 
Xn
Risk Statements:
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
R40:Limited evidence of a carcinogenic effect.
Safety Statements:
S22:Do not breathe dust.
S36:Wear suitable protective clothing.
| 1. |
|
sln-dmg-par 20 mmol/L
|
|
BCPCA6 Biochemical Pharmacology. 15 (1966),299. |
| 2. |
|
spm-rat-ipr 2 g/kg
|
|
CEFYAD Ceskoslovenska Fysiologie. 21 (1972),278. |
| 3. |
|
dni-mus-ipr 3 g/kg
|
|
NEOLA4 Neoplasma. 20 (1973),243. |
| 4. |
|
spm-mus-ipr 5 g/kg
|
|
CEFYAD Ceskoslovenska Fysiologie. 21 (1972),278. |
| 5. |
|
ivn-wmn TDLo:150 mg/kg (47D preg):TER
|
|
CLPTAT Clinical Pharmacology and Therapeutics. 7 (1966),162. |
| 6. |
|
ipr-rat LD50:9400 mg/kg
|
|
TJADAB Teratology, A Journal of Abnormal Development. 4 (1971),287. |
| 7. |
|
ipr-mus LD50:11,250 mg/kg
|
|
BCPCA6 Biochemical Pharmacology. 14 (1965),1517. |
| 8. |
|
ipr-dog LD50:3400 mg/kg
|
|
BCPCA6 Biochemical Pharmacology. 14 (1965),1537. |
| 9. |
|
ipr-cat LD50:2400 mg/kg
|
|
BCPCA6 Biochemical Pharmacology. 14 (1965),1537. |
